Join experienced faculty for the fifth edition of LAAC Summit! Register now to understand patient selection, imaging, transseptal access and expert approaches in treating NVAF patients with ablation and LAAC therapy. bostonsci.co/CW4d30gqnMb Arian Sultan Dr Philippe Garot Renate Schnabel

4 weeks to go to the LAAC summit online. Sign up here!

🌟 Uncover the latest clinical evidence on LAAC therapy for Atrial Fibrillation at the upcoming #LAACSummit on 24, 25 & 26 September! 🔗 Register for free now 👉 ow.ly/qBXY50TjIH6 By attending, you will gain crucial insights on: 🧠 Managing LAAC procedures for high-risk

LAAC using WATCHMAN FLX with @BorisSchmidt5 and Julian Chun After discussion with the panel the device is repositioned slightly deeper, ensuring optimal compression for effective closure of the appendage Dr. Devi G Nair Arian Sultan Andreas Metzner Richard Schilling #EPeeps

Are you signed up to the LAAC summit? Register here to hear the latest updates from experts in LAAC! #BSC

I am really excited for this! Starting today, we will hear from experts in LAAC. The first episode is about stroke prevention in NVAF, are we getting it right? Send to your colleagues and referring networks if you haven’t. 5pm-7pmCEST (4pm uk time)! See you there!

Don’t miss results from the OPTION Clinical Trial, presented at #AHA24! This pivotal study compares the safety & effectiveness of the WATCHMAN FLX™ #LAAC device to oral anticoagulation for stroke protection post-ablation. Learn more about OPTION: bit.ly/3YAXeG2

16th November! Mark your calendars!

What a productive day! It was an honor to share knowledge with some true legends in Structural Interventional Cardiology & inspire the next generation. All the effort put into organizing this course was absolutely worth it

Great to see LAAO on the agenda in the UK!

This Saturday at #AHA24, Dr. Oussama Wazni will present results from the OPTION Clinical Trial! Don’t miss the outcomes of this pivotal study comparing the safety & effectiveness of the WATCHMAN FLX™ #LAAC device to oral anticoagulation for stroke protection post-ablation. For

RCT data vs NOACs presented Saturday!

OPTION Results presented at #AHA24

The much awaited OPTION trial results are out at #AHA24 LAAC better than OAC for bleeding in Patients undergoing AF ablation

We have a new #option for our AF patients! 🚨🚨 Presented at #AHA and now online at #NEJM: The #OPTION trial: ✅1600 pts with AF after catheter ablation and CHA2DS2-VASc (≥2 in men and ≥3 in women) ✅ 1:1 LAAC or OAC. 🙏Oussama Wazni @BorisSchmidt5 Dr. Devi G Nair @boersma_lucas

PRIMARY ENDPOINTS MET! We are excited to announce the positive results from OPTION Clinical Trial – the primary endpoints showed WATCHMAN FLX™ was equally effective to OACs, with a superior safety profile at 36 months, which allowed patients to eliminate continuous medication

Thoroughly enjoyed yesterday’s agenda at BCIS structural day in London. Fantastic to see LAAO included in the discussion once again!

New OPTION concomitant and sequential cohort subanalysis data reaffirms positive primary endpoint outcomes! Consistent with the overall primary outcomes, WATCHMAN FLX™ LAAC Device demonstrated equal thromboembolic protection to OAC (95% DOACs) at 36 months, while significantly

Watch how the WATCHMAN TruSteer™ Access System enabled Thomas Waggoner to treat this heavily pectinated appendage with a WATCHMAN FLX™ Pro #LAAC Device: · Placed the distal end of the device in the anterior space · Mid-deploy steering to keep the device shoulders coaxial ·

Calling all European left atrial appendage occlusion operators - please consider completing our EHRA Scientific Initiatives Committee survey 🫀 It’s very quick! Link: surveymonkey.com/r/LAAC?utm_med… #EPeeps Julian Chun Lukas Urbanek Christian-H. Heeger